Pharmaceutical firm, Cadila Healthcare on Monday said USFDA has given its nod it for the company's three products, taking the group's total number of approvals to 22.
The company would market all the three drugs -- Azathioprine Tablets, belonging to the immuno-suppressant segment, Divalproex Sodium Extended Release, an anti-convulsant and Venlafaxine Hydrochloride Tablets, an anti-depressant -- through its US subsidia ry Zydus Pharmaceuticals (USA) Inc.
The group received approvals to market Azathioprine Tablets of 50 mg, tentative approvals for Divalproex Sodium Extended Release Tablets of 250 and 500 mg and Venlafaxine Hydrochloride Tablets of 25, 37.5, 50, 75 and 100 mg, Cadila Healthcare informed BSE.
Read more at The Hindu Business Line
